Innovations in point of care testing for bacterial infections: The Longitude Prize with Daniel Berman

Video Journal of Biomedicine | Expert Perspective

Antimicrobial resistance (AMR) is one of the most serious clinical and public healthcare challenges. In this video Daniel BermanNesta Challenges, provides an overview of the Longitude Prize, why the prize was set up and what the prize hopes to achieve. Daniel also provides insight into some of the rapid diagnostic tests currently in the running for the £8 million prize.

Related videos:

To learn more about how rapid diagnostic tests could overcome resistance to antibiotics, watch our companion interview ‘Re-challenging antibiotic resistance with Daniel Berman‘.

About the author:

Daniel Berman is Head of the Global Health Team, including the Longitude Prize, at Nesta Challenges. Prior to Nesta, Daniel worked for the World Health Organization in Ethiopia on a local pharmaceutical production project. Previous to that he was at Médecins Sans Frontières (MSF) for more than 16 years. At MSF he had multiple assignments in the Access to Medicines Campaign which focuses on stimulating and steering innovation and access to medicines, diagnostics and vaccines. From 2012-2015 Daniel was General Director of MSF Southern Africa, based in Johannesburg, South Africa. Daniel is currently a Trustee for QUAMED, a French NGO that supports humanitarian organisations and national procurement institutions to improving the quality of medicines.

About the prize:

The Longitude Prize is a £10 million project designed to incentivise the development of a rapid diagnostic test to improve the use of antibiotics. Daniel represents Nesta in international One Health forums designed to address the challenge of AMR. This includes championing new strategies to address the market failure that has led to a lack of diagnostic products to address AMR.